GlassScriptPhysician profile
Kathy A Tran
NPI 1306133905
$8,761.07
in general payments reported to CMS, 2019-2025
41 companies · $2,042 in 2025
The $2,042 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $947 · 2020: $598 · 2021: $977 · 2022: $1,379 · 2023: $1,382 · 2024: $1,437 · 2025: $2,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,743 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,743.49 |
| Education | $117.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,597.32 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,028.45 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Harmony Biosciences LLC | $826.68 | 2020-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $658.85 | 2019-2025 | Dupixent |
| Insmed, INC. | $626.62 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $557.36 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $514.75 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $489.24 | 2019-2025 | Ofev, Jascayd |
| Actelion Pharmaceuticals US, INC. | $305.71 | 2020-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $188.73 | 2019-2024 | Tyvaso |
| Mylan Specialty L.P. | $181.86 | 2019-2024 | Yupelri |
| Verona Pharma, INC. | $151.14 | 2025 | Ohtuvayre |
| Philips North America LLC | $150.32 | 2020-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Pulmonx Corporation | $138.35 | 2023-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Sanofi-Aventis U.S. LLC | $120.53 | 2019-2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $114.27 | 2022-2025 | Smartvest |
| Pfizer INC. | $106.13 | 2021-2025 | |
| Resmed Corp | $82.68 | 2020-2024 | |
| Amgen INC. | $74.10 | 2023-2024 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $69.52 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $67.05 | 2023-2024 | Acthar |
| Merck Sharp & Dohme LLC | $65.88 | 2019-2023 | Belsomra |
| Ani Pharmaceuticals, INC. | $55.33 | 2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $54.37 | 2021-2022 | |
| Axsome Therapeutics, INC. | $51.72 | 2024-2025 | Sunosi |
| Bayer Healthcare Pharmaceuticals INC. | $49.41 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $48.39 | 2023 | |
| Sunovion Pharmaceuticals INC. | $47.44 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $44.54 | 2024 | Lumryz |
| Vifor Pharma, INC. | $40.83 | 2025 | Veltassa, Zemaira |
| Inspire Medical Systems, INC. | $35.88 | 2023-2025 | Inspire |
| Genentech USA, INC. | $31.14 | 2019-2020 | |
| Tactile Systems Technology INC | $29.53 | 2025 | Flexitouch Plus, Nimbl |
| Janssen Pharmaceuticals, INC | $28.43 | 2021 | |
| Csl Behring | $24.26 | 2019 | |
| Vapotherm INC | $18.46 | 2021 | |
| Grifols USA, LLC | $17.86 | 2025 | Xembify |
| Circassia INC. | $17.47 | 2019 | |
| Shire North American Group INC | $17.46 | 2019 | |
| Inogen, INC. | $16.87 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Teva Pharmaceuticals USA, INC. | $16.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.